The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Official Title: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Study ID: NCT04221542
Brief Summary: Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
City of Hope National Medical Center, Duarte, California, United States
Providence Saint Jude Medical Center, Fullerton, California, United States
University of California San Francisco, San Francisco, California, United States
Yale Cancer Center, New Haven, Connecticut, United States
Emory University, Atlanta, Georgia, United States
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Alliance for Multispecialty Research, Merriam, Kansas, United States
Tulane Medical Center, New Orleans, Louisiana, United States
Washington University, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Oncology Hematology Care Incorporated, Cincinnati, Ohio, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Cancer Pavillion, Pittsburgh, Pennsylvania, United States
Prisma Health Upstate, Greenville, South Carolina, United States
Sanford Health, Sioux Falls, South Dakota, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Virginia Cancer Specialists PC, Fairfax, Virginia, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
Monash Medical Centre, Clayton, Victoria, Australia
Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China
Fudan University Shanghai Cancer Centre, Shanghai, Shanghai, China
Zhejiang Provincial Peoples Hospital, Hangzhou, Zhejiang, China
Universitaetsklinikum Essen, Essen, , Germany
Universitaetsklinikum Heidelberg, Heidelberg, , Germany
Klinikum rechts der Isar der TUM, Muenchen, , Germany
Universitaetsklinikum Muenster, Muenster, , Germany
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Yokohama City University Hospital, Yokohama-shi, Kanagawa, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan
Seoul National University Hospital, Seoul, , Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
Hospital da Luz, SA, Lisboa, , Portugal
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto, , Portugal
Hospital Universitari Vall d Hebron, Barcelona, Cataluña, Spain
Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña, Spain
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
Hospital Clinico San Carlos, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Istituto Oncologico della Svizzera Italiana, Bellinzona, , Switzerland
Kantonsspital Graubuenden, Chur, , Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland
Kantonsspital Sankt Gallen, Sankt Gallen, , Switzerland
National Taiwan University Hospital, Taipei, , Taiwan
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, , Taiwan
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR